Market Research Logo

Multiple Sclerosis Market in the US 2015-2019

Multiple Sclerosis Market in the US 2015-2019

About Multiple Sclerosis

Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with severe form of the disease can experience speech and movement problems. Multiple sclerosis can be broadly classified into four types: RRMS, SPMS, PPMS, and PRMS.

Technavio's analysts forecast the multiple sclerosis market in the US to grow at a CAGR of 3.8% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the multiple sclerosis market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of multiple sclerosis.On the basis of route of administration of the drugs, the market is grouped into the following categories:

  • Oral
  • Parenteral
On the basis of type of molecule of the drugs, the market is grouped into the following categories:
  • Small Molecules
  • Biologics
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors and competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio's report, the multiple sclerosis market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the multiple sclerosis market in US market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors
  • Bayer AG
  • Biogen
  • Merck Serono
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
Other Prominent Vendors
  • AB Science
  • Abbvie
  • Acorda Therapeutics
  • Active Biotech
  • Artielle
  • Astellas
  • AstraZeneca
  • Canbex
  • F. Hoffmann-La Roche
  • GeNeuro
  • GlaxoSmithKline
  • Glenmark
  • InnoBioscience Pharmaceuticals
  • Ipsen
  • Mapi-Pharma
  • medDay Pharmaceuticals
  • MediciNova
  • Mitsubishi Tanabe
  • Opexa Therapeutics
  • Osmotica
  • Pfizer
  • Receptos
  • RedHill Biopharma
  • Sanofi
  • Trophos
  • XenoPort
Market Driver
  • Unmet Medical Needs.
  • For a full, detailed list, view our report.
Market Challenge
  • Unknown Disease Etiology.
  • For a full, detailed list, view our report.
Market Trend
  • Introduction of Disease-modifying Drugs.
  • For a full, detailed list, view our report.
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Multiple Sclerosis Market in the US 2015-2019

Technavio recognizes the following companies as the key players in the Multiple Sclerosis Market in the US: Bayer AG, Biogen, Merck Serono, Novartis AG and Teva Pharmaceutical Industries Ltd.

Other Prominent Vendors in the market are: AB Science, Abbvie, Acorda Therapeutics, Active Biotech, Artielle, Astellas, AstraZeneca, Canbex, F. Hoffmann-La Roche, GeNeuro, GlaxoSmithKline, Glenmark, InnoBioscience Pharmaceuticals, Ipsen, Mapi-Pharma, medDay Pharmaceuticals, MediciNova, Mitsubishi Tanabe, Opexa Therapeutics, Osmotica, Pfizer, Receptos, RedHill Biopharma, Sanofi, Trophos and XenoPort

Commenting on the report, an analyst from Technavio’s team said: “The US FDA has approved certain disease-modifying drugs for treating various forms of multiple sclerosis. These drugs interact with the immune system to reduce the number of relapses. Copaxone (glatiramer acetate) by Teva Pharmaceutical, Avonex (interferon beta-1a) and Tysabri (natalizumab) by Biogen, Gilenya (fingolimod) by Novartis, and Betaseron (interferon beta-1b) by Bayer are some of the disease-modifying drugs indicated for the treatment of the disease. Daclizumab by Biogen and BAF312 by Novartis are disease-modifying drugs expected to be launched during the forecast period.”

According to the report, in 2014, currently, medications that can produce the remission of multiple sclerosis in patients are absent. In addition, there are no established treatment procedures for multiple sclerosis. The available drugs in the market are only intended to modify the course of the disease and treat relapses. Some of the drugs are also meant for the symptomatic treatment of the patient and for managing emotional health. Thus, there is a lucrative space for companies that can address the issue of unmet medical needs in the market and develop drugs that can completely cure the disease.Further, the report states that unknown disease etiology has made it difficult for researchers to develop drugs that can target its cause.

Companies Mentioned

Bayer AG, Biogen, Merck Serono, Novartis AG, Teva Pharmaceutical Industries Ltd., AB Science, Abbvie, Acorda Therapeutics, Active Biotech, Artielle, Astellas, AstraZeneca, Canbex, F. Hoffmann-La Roche, GeNeuro, GlaxoSmithKline, Glenmark, InnoBioscience Pharmaceuticals, Ipsen, Mapi-Pharma, medDay Pharmaceuticals, MediciNova, Mitsubishi Tanabe, Opexa Therapeutics, Osmotica, Pfizer, Receptos, RedHill Biopharma, Sanofi, Trophos, XenoPort

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Product Profiles
    • Betaseron/Extavia
      • Avonex/Rebif
      • Tecfidera
      • Tysabri
      • Gilenya
      • Copaxone
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Multiple Sclerosis: An Overview
    • About the Disease
      • Table Frequency of Types of Multiple Sclerosis
      • Signs and Symptoms
      • Etiology
        • Table Etiology of Multiple Sclerosis
      • Epidemiology
      • Economic Burden
  • Market Landscape
    • Market Overview
      • Table Snapshot of Multiple Sclerosis Market in US
    • Market Size and Forecast
      • Table Multiple Sclerosis Market in US 2014-2019 ($ millions)
    • Five Forces Analysis
  • Market Segmentation by Route of Administration
    • Table Segmentation of Multiple Sclerosis Market in US by Route of Administration
    • Table Segmentation of Multiple Sclerosis Market in US by Route of Administration 2014
    • Multiple Sclerosis Market in US by Oral Drugs
      • Market Size and Forecast
        • Table Multiple Sclerosis Market in US by Oral Drugs 2014-2019 ($ millions)
    • Multiple Sclerosis Market in US by Parenteral Drugs
      • Market Size and Forecast
        • Table Multiple Sclerosis Market in US by Parenteral Drugs 2014-2019 ($ millions)
        • Table Segmentation of Multiple Sclerosis Market in US by Route of Administration 2014 ($ millions)
  • Market Segmentation by Type of Molecule
    • Table Segmentation of Multiple Sclerosis Market in US by Type of Molecule
    • Table Segmentation of Multiple Sclerosis Market in US by Type of Molecule 2014
    • Multiple Sclerosis Market in US by Small Molecules
      • Market Size and Forecast
        • Table Multiple Sclerosis Market in US by Small Molecules 2014-2019 ($ millions)
    • Multiple Sclerosis Market in US by Biologics
      • Market Size and Forecast
        • Table Multiple Sclerosis Market in US by Biologics 2014-2019 ($ millions)
        • Table Segmentation of Multiple Sclerosis Market in US by Type of Molecule 2014 ($ millions)
  • Pipeline Portfolio
    • Table Multiple Sclerosis Drugs Under Development
    • Table Multiple Sclerosis Drugs Under Various Developmental Phases
    • Key Information of Late-stage Pipeline Molecules
      • Daclizumab High-yield Process (BIIB019)
      • RPC1063
      • Masitinib
      • Laquinimod
      • Natalizumab
      • Siponimod or BAF312
      • OS-440 (arbaclofen)
      • Ocrelizumab (RG1594)
  • Buying Criteria
  • Market Growth Drivers
    • Table Major Drivers of Multiple Sclerosis Market in US
  • Drivers and Their Impact
  • Market Challenges
    • Table Major Challenges in Multiple Sclerosis Market in US
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Major Trends in Multiple Sclerosis Market in US
  • Trends and Their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Competitive Landscape of Multiple Sclerosis Market in US
        • Table Global Revenues of Top-selling Drugs for Multiple Sclerosis 2014 ($ millions)
        • Table YoY Global Growth of Top-selling Drugs for Multiple Sclerosis 2012-2014 ($ millions)
      • Biogen
        • Table Biogen: YoY Global Revenue of Avonex 2011-2014 ($ millions)
        • Table Biogen: Revenue of Avonex in US 2011-2014 ($ millions)
        • Table Biogen: Revenue of Avonex in ROW 2011-2014 ($ millions)
        • Table Biogen: YoY Global Revenue of Tysabri 2011-2014 ($ millions)
        • Table Biogen: Revenue of Tysabri in US 2011-2014 ($ millions)
        • Table Biogen: Revenue of Tysabri in ROW 2011-2014 ($ millions)
        • Table Biogen: Revenue of Plegridy in US and ROW 2014 ($ millions)
        • Table Biogen: Revenue of Tecfidera in US and ROW 2014 ($ millions)
      • Teva Pharmaceutical
        • Table Teva Pharmaceutical: YoY Global Revenue of Copaxone 2011-2014 ($ millions)
        • Table Teva Pharmaceutical: Quarter-wise Revenue of Copaxone 2011-2014 ($ millions)
      • Novartis
        • Table Novartis: YoY Global Revenue of Gilenya 2011-2014 ($ millions)
        • Table Novartis: Revenue of Gilenya in US and ROW 2011-2013 ($ millions)
        • Table Novartis: YoY Global Revenue of Extavia 2011-2014 ($ millions)
      • Merck Serono
        • Table Merck Serono: YoY Global Revenue of Rebif 2011-2014 ($ millions)
        • Table Merck Serono: Revenue of Rebif in North America 2011-2014 ($ millions)
        • Table Merck Serono: Revenue of Rebif in Europe 2011-2014 ($ millions)
        • Table Merck Serono: Revenue Share of Rebif by Region 2012-2014
      • Bayer
        • Table Bayer: YoY Global Revenue of Betaseron 2011-2014 ($ millions)
    • Other and Future Prominent Vendors
  • Key Vendor Analysis
    • Bayer
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2014
        • Table Bayer: Business Segmentation by Revenue 2014
      • Business Segmentation by Revenue 2013 and 2014
        • Table Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
      • Geographical Segmentation by Revenue 2014
        • Table Bayer: Geographical Segmentation by Revenue 2014
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Biogen
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Biogen: Business Segmentation by Revenue 2013
      • Geographical Segmentation by Revenue 2013
        • Table Biogen: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Merck Serono
      • Key Facts
      • Business Overview
      • Geographical Segmentation by Revenue 2013
        • Table Merck Serono: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Novartis
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Novartis: Business Segmentation
      • Revenue by Business Segmentation
        • Table Novartis: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table Novartis: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Teva Pharmaceutical
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Teva Pharmaceutical: Business Segmentation
      • Revenue by Business Segmentation
        • Table Teva Pharmaceutical: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Teva Pharmaceutical: Revenue by Business Segmentation 2012 and 2013 ($ millions)
      • Revenue Segmentation by Geography
        • Table Teva Pharmaceutical: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in This Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report